$514 Million is the total value of GREAT POINT PARTNERS LLC's 39 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 65.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ZGNX | Sell | ZOGENIX INC | $35,798,000 | +1.1% | 1,021,331 | -58.2% | 6.96% | +9.8% |
| UTHR | New | UNITED THERAPEUTICS CORP DELcall | $35,157,000 | – | 300,000 | +100.0% | 6.84% | – |
| ARNA | Sell | ARENA PHARMACEUTICALS INC | $34,624,000 | -15.9% | 1,357,800 | -44.4% | 6.74% | -8.7% |
| CNCE | Buy | CONCERT PHARMACEUTICALS INC | $29,592,000 | +6.1% | 2,006,211 | +0.3% | 5.76% | +15.2% |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCput | $29,373,000 | – | 250,000 | +100.0% | 5.71% | – |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $29,108,000 | +5.5% | 475,000 | -20.8% | 5.66% | +14.5% |
| FOMX | FOAMIX PHARMACEUTICALS LTD | $26,538,000 | +19.6% | 4,781,708 | 0.0% | 5.16% | +29.9% | |
| KURA | New | KURA ONCOLOGY INC | $26,176,000 | – | 1,750,887 | +100.0% | 5.09% | – |
| RIGL | RIGEL PHARMACEUTICALS INC | $23,128,000 | -7.0% | 9,105,691 | 0.0% | 4.50% | +1.0% | |
| PTCT | Sell | PTC THERAPEUTICS INC | $22,011,000 | -36.8% | 1,100,000 | -42.1% | 4.28% | -31.4% |
| DBVT | Sell | DBV TECHNOLOGIES SAsponsored adr | $19,136,000 | +7.2% | 450,888 | -9.8% | 3.72% | +16.4% |
| ZGNX | New | ZOGENIX INCcall | $17,525,000 | – | 500,000 | +100.0% | 3.41% | – |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $17,403,000 | +149.1% | 560,498 | +119.5% | 3.39% | +170.7% |
| SELB | Sell | SELECTA BIOSCIENCES INC | $16,459,000 | -11.6% | 901,847 | -3.8% | 3.20% | -4.0% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $15,500,000 | +1148.0% | 2,000,000 | +1083.3% | 3.02% | +1252.0% |
| RXDX | Sell | IGNYTA INC | $15,336,000 | -15.3% | 1,241,752 | -29.0% | 2.98% | -8.0% |
| ZGNX | New | ZOGENIX INCput | $13,144,000 | – | 375,000 | +100.0% | 2.56% | – |
| AIMT | Buy | AIMMUNE THERAPEUTICS INC | $12,395,000 | +38.5% | 500,000 | +14.8% | 2.41% | +50.3% |
| SRPT | New | SAREPTA THERAPEUTICS INC | $11,340,000 | – | 250,000 | +100.0% | 2.21% | – |
| SGYPQ | Sell | SYNERGY PHARMACEUTICALS DEL | $9,493,000 | -70.5% | 3,273,509 | -54.7% | 1.85% | -67.9% |
| PTCT | Buy | PTC THERAPEUTICS INCcall | $9,205,000 | +93.1% | 460,000 | +76.9% | 1.79% | +109.7% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $8,906,000 | -75.5% | 497,531 | -77.7% | 1.73% | -73.4% |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $8,580,000 | – | 1,637,332 | +100.0% | 1.67% | – |
| SAGE | Sell | SAGE THERAPEUTICS INC | $6,822,000 | -64.9% | 109,500 | -55.1% | 1.33% | -61.8% |
| XLRN | Sell | ACCELERON PHARMA INC | $6,344,000 | -57.7% | 170,000 | -65.6% | 1.23% | -54.1% |
| BVX | Sell | BOVIE MEDICAL CORP | $6,184,000 | -14.4% | 1,829,441 | -37.4% | 1.20% | -7.0% |
| ADMS | Sell | ADAMAS PHARMACEUTICALS INC | $5,427,000 | -86.0% | 256,340 | -88.4% | 1.06% | -84.8% |
| MCRB | New | SERES THERAPEUTICS INCput | $4,411,000 | – | 275,000 | +100.0% | 0.86% | – |
| AMRN | Sell | AMARIN CORPORATION PLCspons adr new | $3,699,000 | -48.1% | 1,056,825 | -40.3% | 0.72% | -43.7% |
| MYOV | Sell | MYOVANT SCIENCES LTD | $3,527,000 | +21.6% | 228,008 | -8.0% | 0.69% | +31.9% |
| NVCR | New | NOVOCURE LTD | $3,527,000 | – | 177,666 | +100.0% | 0.69% | – |
| SNSS | Buy | SUNESIS PHARMACEUTICALS INC | $2,828,000 | -26.8% | 1,457,712 | +1.9% | 0.55% | -20.5% |
| CNXR | CONNECTURE INC | $2,765,000 | +8.4% | 4,127,232 | 0.0% | 0.54% | +17.7% | |
| AGRX | New | AGILE THERAPEUTICS INC | $1,620,000 | – | 363,299 | +100.0% | 0.32% | – |
| ARDX | New | ARDELYX INC | $691,000 | – | 123,316 | +100.0% | 0.13% | – |
| STRM | STREAMLINE HEALTH SOLUTIONS | $191,000 | +37.4% | 130,137 | 0.0% | 0.04% | +48.0% | |
| AXGT | New | AXOVANT SCIENCES LTD | $67,000 | – | 9,679 | +100.0% | 0.01% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INCcall | $0 | – | -12,400 | -100.0% | -0.02% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -49,471 | -100.0% | -0.14% | – |
| ARDMQ | Exit | ARADIGM CORP | $0 | – | -637,279 | -100.0% | -0.15% | – |
| SAGE | Exit | SAGE THERAPEUTICS INCput | $0 | – | -51,600 | -100.0% | -0.74% | – |
| CARA | Exit | CARA THERAPEUTICS INCput | $0 | – | -271,400 | -100.0% | -0.75% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -435,500 | -100.0% | -0.75% | – |
| NLNK | Exit | NEWLINK GENETICS CORP | $0 | – | -1,092,849 | -100.0% | -1.44% | – |
| INSM | Exit | INSMED INC | $0 | – | -538,473 | -100.0% | -1.66% | – |
| Exit | NEURODERM LTD | $0 | – | -311,000 | -100.0% | -1.67% | – | |
| PTLA | Exit | PORTOLA PHARMACEUTICALS INCcall | $0 | – | -216,200 | -100.0% | -2.18% | – |
| SGEN | Exit | SEATTLE GENETICS INCcall | $0 | – | -249,500 | -100.0% | -2.31% | – |
| PCRX | Exit | PACIRA PHARMACEUTICALS INC | $0 | – | -300,000 | -100.0% | -2.56% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -276,800 | -100.0% | -3.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.